Pharmaceutical preparations for the treatment of liver disease and monogenic disease; pharmaceutical preparations for the treatment of metabolic disorders, or central nervous system disorders; pharmaceutical preparations for the treatment of focal segmental glomerulosclerosis (FSGS); pharmaceutical preparations for the treatment of Alport Syndrome; pharmaceutical preparations for the treatment of glomerulonephropathy; pharmaceutical preparations for the treatment of glomerulonephritis